Galmarini, Carlos M. published the artcileOSI-461 (OSI), COA of Formula: C20H17FO4S, the publication is Current Opinion in Investigational Drugs (Thomson Scientific) (2004), 5(6), 648-656, database is CAplus and MEDLINE.
A review. OSI Pharmaceuticals is developing OSI-461, a potent analog of exisulind, for the potential treatment of cancer and inflammatory bowel disease. In August 2001, OSI-461 entered phase II trials involving patients with chronic lymphocytic leukemia. In July 2002, the company embarked on a pilot phase II study evaluating OSI-461 for the treatment of Crohn’s disease. By Oct. 2002, Cell Pathways had selected hormone-refractory prostate cancer as the lead cancer indication for clin. development of OSI-461.
Current Opinion in Investigational Drugs (Thomson Scientific) published new progress about 59973-80-7. 59973-80-7 belongs to naphthyridine, auxiliary class Immunology/Inflammation,COX, name is Sulindac sulfone, and the molecular formula is C20H17FO4S, COA of Formula: C20H17FO4S.
Referemce:
https://en.wikipedia.org/wiki/1,8-Naphthyridine,
1,8-Naphthyridine | C8H6N2 – PubChem